Fixed-Dose Carteolol/Latanoprost Combination

Monotherapy may be insufficient to lower intraocular pressure (IOP) for some patients with glaucoma, but therapy with 2 agents may be
incon­venient and result in poor adherence. Yamamoto et al. reported
results of 2 phase 3 randomized controlled trials in which a fixed-dose
combination of 2% carteolol and 0.005% latanoprost, given as a single
therapeutic (termed OPC-1085EL), was evaluated for safety and efficacy.
OPC-1085EL was com­pared with carteolol and latanoprost administered as
monotherapies or as separate concomitant therapies. The authors found
that OPC-1085EL was well tolerated and reduced IOP more than the
monotherapy and comparably to the concomitant therapy.wisepoqder Carteolol powder

The trials were conducted at several centers in Japan and included patients with bilateral primary open-angle glau­coma or ocular
hypertension. After a 4-week period with latanoprost or car­teolol
monotherapy, patients received 8 weeks of treatment with monotherapy,
concomitant therapy, or OPC-1085EL applied daily in the morning.

In study 1, the mean reduction in baseline-adjusted IOP for the 113 patients treated with OPC-1085EL (2.9 mm Hg) was significantly better
than for the 116 patients treated with latanoprost monotherapy (1.6 mm
Hg). In study 2, the mean reduction in baseline-adjusted IOP was
significantly better for OPC-1085EL (n = 76; 3.5 mm Hg) than for
carteolol (n = 76; 1.6 mm Hg). IOP reduction in the 37 patients who
received carteolol and latanoprost concomitantly was similar to that in
recipients of OPC-1085EL. In both studies, OPC-1085EL was toler­ated
well and associated with only mild adverse drug reactions.

The authors concluded that OPC-1085EL is similar to concomitant ther­apy in terms of IOP-reducing efficacy but offers greater
convenience. They noted that subsequent studies are need­ed to evaluate
it for a longer duration, administered at other times of day, and in
more diverse populations.